Clindamycin phosphate

• UNSPSC Description:

  Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis[1][2][3].Clindamycin phosphate has no cytotoxicity。 Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties[4].

• Target Antigen:

  Antibiotic; Bacterial; Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/clindamycin-phosphate.html

• Purity:

  98.0

• Solubility:

  H2O : ≥ 320 mg/mL

• Smiles:

  CCC[C@H]1CN(C)[C@H](C(N[C@@]([H])([C@@]2([H])O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O)[C@@H](Cl)C)=O)C1

• Molecular Weight:

  504.96

• References & Citations:

  [1]Li H, et al. Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. Eur J Clin Pharmacol. 2017 Feb;73(2):251-253.|[2]Hayashi N, et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study. J Dermatol. 2018 Aug;45(8):951-962.|[3]A. Dupre, et al. Proof of concept study of a novel bioadhesive clindamycin phosphate 2% vaginal gel to treat bacterial vaginosis. Clin. Exp. Obstet. Gynecol. 2020, 47(4), 516–518|[4]Egle K, et al.Injectable Platelet-Rich Fibrin as a Drug Carrier Increases the Antibacterial Susceptibility of Antibiotic-Clindamycin Phosphate. Int J Mol Sci. 2022 Jul 3;23(13):7407EBioMedicine. 2022 Apr;78:103943.|ACS Omega. March 3, 2022.|Acta Pharm Sin B. 2021 Mar 11.|Dermatol Clin. 2024 September 12.|EBioMedicine. 2022 Apr;78:103943.|Water Res. 2023 May 21, 120110.|bioRxiv. 2024 Jan 18.|bioRxiv. 2024 May 10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  24729-96-2